The HIV entry inhibitors revisited

Area of Science:

• Virology
• Pharmacology
• Drug Discovery

Background:

• Emerging HIV-1 entry inhibitors represent a new class of antivirals with distinct mechanisms and toxicity profiles compared to existing treatments.
• Resistance to current combination therapies necessitates the development of novel therapeutic strategies targeting early stages of viral infection.
• Understanding the molecular mechanisms of HIV-1 entry is crucial for designing effective interventions.

Purpose of the Study:

• To review recent developments in HIV entry inhibitors, focusing on their mechanisms of action, structural and functional aspects.
• To summarize insights into small-molecule antagonist interactions with HIV-1 coreceptors CCR5 and CXCR4.
• To provide an overview of preclinical and early clinical entry inhibitors and relevant Quantitative Structure-Activity Relationships (QSAR) studies.

Main Methods:

• Review of scientific literature on HIV-1 entry inhibitors and their mechanisms.
• Analysis of small-molecule antagonists targeting CCR5 and CXCR4.
• Summary of drug development programs and QSAR studies for coreceptor antagonists.

Main Results:

• HIV entry inhibitors operate early in the viral life cycle, preventing viral entry with high specificity and low toxicity.
• CCR5 and CXCR4 are key coreceptors for HIV-1 entry, making them attractive targets for drug development.
• Several small-molecule antagonists of CCR5 and CXCR4 have been identified, with some showing synergistic effects with other antivirals.

Conclusions:

• HIV entry inhibitors offer a promising strategy to overcome resistance to existing therapies.
• Targeting HIV-1 coreceptors like CCR5 and CXCR4 is a viable approach for developing new antiviral drugs.
• Continued research into entry inhibitors and their interactions with coreceptors is essential for advancing HIV treatment.